Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brassat, D.
Right arrow Articles by Clanet, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brassat, D.
Right arrow Articles by Clanet, M.
Related Collections
Right arrow Hematologic
Right arrow All Clinical trials
Right arrow Multiple sclerosis

Neurology 2002;59:954-955
© 2002 American Academy of Neurology
Brief Communications

Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS

D. Brassat, MD, C. Recher, MD, E. Waubant, MD, E. Le Page, MD, F. Rigal-Huguet, MD, G. Laurent, MD, G. Edan, MD and M. Clanet, MD

From the Departments of Neurology (Drs. Brassat and Clanet) and Haematology (Drs. Recher, Rigal-Huguet and Laurent) Hôpital Purpan, Toulouse University Medical Center, Toulouse; the Department of Neurology (Drs. Le Page and Edan), Hôpital Ponchaillou, Rennes, France; and Multiple Sclerosis Center (Dr. Waubant) UCSF, San Francisco, CA.

Address correspondence and reprint requests to Dr. David Brassat, Fédération de Neurologie, Hôpital Purpan, Place du Dr Baylac, 31059 Toulouse Cédex France; e-mail dbrassat{at}yahoo.fr

The authors report a patient with severe secondary progressive MS who responded to mitoxantrone but developed a fatal acute myeloblastic leukemia 15 months after completion of mitoxantrone therapy. Therapy-related acute leukemia (TRAL) in relation with mitoxantrone is rare; this patient was the first case among a cohort of 802 French MS patients treated with mitoxantrone. Nevertheless, this case stresses the need to further evaluate the long-term risk of TRAL in patients with MS who receive mitoxantrone.




This article has been cited by other articles:


Home page
 BloodHome page
S. K. Hasan, A. N. Mays, T. Ottone, A. Ledda, G. La Nasa, C. Cattaneo, E. Borlenghi, L. Melillo, E. Montefusco, J. Cervera, et al.
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis
Blood, October 15, 2008; 112(8): 3383 - 3390.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
C. Lebrun, M. Debouverie, P. Vermersch, P. Clavelou, L. Rumbach, J. de Seze, S. Wiertlevski, G. Defer, O. Gout, F. Berthier, et al.
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
Multiple Sclerosis, April 1, 2008; 14(3): 399 - 405.
[Abstract] [PDF]

Home page
 Mult SclerHome page
S. A. Sadiq, M. Rammal, and G. Sara
Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS
Multiple Sclerosis, March 1, 2008; 14(2): 272 - 273.
[Abstract] [PDF]

Home page
 NeurologyHome page
B. A. Cohen and D. D. Mikol
Mitoxantrone treatment of multiple sclerosis: Safety considerations
Neurology, December 28, 2004; 63(12_suppl_6): S28 - S32.
[Abstract] [Full Text]

Home page
 Mult SclerHome page
R. Voltz, M. Starck, V. Zingler, M. Strupp, and H.-J. Kolb
Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients
Multiple Sclerosis, August 1, 2004; 10(4): 472 - 474.
[Abstract] [PDF]

Home page
 Mult SclerHome page
B Delisse, J de Seze, A Mackowiak, J B N'Kendjuo, A Verier, O Derepeer, C Boisselier, P Devos, P Hautecoeur, P Vermersch, et al.
Letter to the editor
Multiple Sclerosis, February 1, 2004; 10(1): 92 - 92.
[PDF]

Home page
 The Annals of PharmacotherapyHome page
Retraction: acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis.
Ann. Pharmacother., January 1, 2004; 38(1): 176 - 177.
[Full Text]

Home page
 NeurologyHome page
D.S. Goodin, B.G. Arnason, P.K. Coyle, E.M. Frohman, and D.W. Paty
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, November 25, 2003; 61(10): 1332 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. H. Jaster, H. B. Niell, F. C. Dohan Jr., T. W. Smith, D. Brassat, C. Recher, F. Rigal-Huguet, G. Laurent, M. Clanet, E. Waubant, et al.
Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS
Neurology, April 22, 2003; 60(8): 1399 - 1400.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS
J Howard Jaster, et al.
Neurology Online, 22 Jan 2003 [Full text]
Reply to Letter to the Editor
David Brassat
Neurology Online, 22 Jan 2003 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.